TrialCardiovascular therapeutics2015

A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients.

David J Polhemus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.